The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 311-314

  Van Schie, K A ^a,b   Hart, M H ^a,b   De Groot, E R ^a,b   Kruithof, S ^a,b   Aarden, L A ^a,b   Wolbink, G J ^a,b,c   Rispens, T ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Jan Van Breemen Research Instituut   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHIMERA; CONCENTRATION RESPONSE; DRUG PROTEIN BINDING; HUMAN; IMMUNOASSAY; PROTEIN DOMAIN; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; ANTIBODY COMBINING SITE; IMMUNOLOGY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIRHEUMATIC AGENTS; BINDING SITES, ANTIBODY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918578141     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206237     Document Type: Article

References (11)

1. Van Schouwenburg PA, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
2. Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J Am Med Assoc 2011;305:1460-8.
3. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
4. Paolicelli D, D'Onghia M, Pellegrini F, et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon â-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 2013;260:1562-8.
5. Van Schouwenburg PA, Van De Stadt LA, De Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
6. Kosmac M, Avcin T, Toplak N, et al. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res 2011;69:243-8.
7. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34.
8. Chatenoud L, Baudrihaye MF, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986;137:830-8. http://www.ncbi.nlm.nih.gov/pubmed/3487589
9. Van Mierlo GJD, Cnubben NHP, Wouters D, et al. The minipig as an alternative non-rodent model for immunogenicity testing using the TNFá blockers adalimumab and infliximab. J Immunotoxicol 2014;11:62-71.
10. Liang S, Dai J, Hou S, et al. Structural basis for treating tumor necrosis factor á (TNFá)-associated diseases with the therapeutic antibody infliximab. J Biol Chem 2013;288:13799-807.
11. Hu S, Liang S, Guo H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor á-associated diseases from a molecular view. J Biol Chem 2013;288:27059-67.